Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Mar;67(3):537–543.

Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy

Wilma Barcellini, P L Meroni, Daniela Frasca, Chiara Sguotti, Maria Orietta Borghi, Caterina Uberti-Foppa, P Buzzetti, A Lazzarin, G Doria, M Moroni, C Zanussi
PMCID: PMC1542610  PMID: 3301099

Abstract

The effect of thymopentin treatment on the immune defects in drug addicts with persistent generalized lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 mg/week for 3 months (second cycle). After the first cycle an increased number of OKT4+ lymphocytes and an improvement of PWM-induced blastogenesis and IgG synthesis in vitro was observed. The second cycle was unable to modify the same immune parameters in vitro. The treatment had no effect on the PHA responsiveness and on PHA-induced interleukin 2 production. The significance and the prognostic value of these findings are discussed in terms of the clinical evolution of the syndrome.

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Audhya T., Goldstein G. Comparative efficacy of various routes of administration of thymopentin (TP-5) with consideration of degradative mechanisms. Int J Pept Protein Res. 1983 Aug;22(2):187–193. doi: 10.1111/j.1399-3011.1983.tb02085.x. [DOI] [PubMed] [Google Scholar]
  2. Audhya T., Goldstein G. Thymopentin (TP-5) potency in vivo is enhanced by slow infusion. Int J Pept Protein Res. 1983 Nov;22(5):568–572. doi: 10.1111/j.1399-3011.1983.tb02130.x. [DOI] [PubMed] [Google Scholar]
  3. Barcellini W., Meroni P. L., Lazzarin A., Sguotti C., Parravicini C., Borghi M. O., Brucato A., Moroni M., Sirianni M. C., Aiuti F. Persistent generalized lymphadenopathy in drug addicts: immunological studies. Boll Ist Sieroter Milan. 1986;65(4):269–276. [PubMed] [Google Scholar]
  4. Bowen D. L., Lane H. C., Fauci A. S. Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Nov;103(5):704–709. doi: 10.7326/0003-4819-103-5-704. [DOI] [PubMed] [Google Scholar]
  5. Dardenne M., Bach J. F., Safai B. Low serum thymic hormone levels in patients with acquired immunodeficiency syndrome. N Engl J Med. 1983 Jul 7;309(1):48–49. doi: 10.1056/NEJM198307073090112. [DOI] [PubMed] [Google Scholar]
  6. Fauci A. S., Macher A. M., Longo D. L., Lane H. C., Rook A. H., Masur H., Gelmann E. P. NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med. 1984 Jan;100(1):92–106. doi: 10.7326/0003-4819-100-1-92. [DOI] [PubMed] [Google Scholar]
  7. Francis D. P., Jaffe H. W., Fultz P. N., Getchell J. P., McDougal J. S., Feorino P. M. The natural history of infection with the lymphadenopathy-associated virus/human T-lymphotropic virus type III. Ann Intern Med. 1985 Nov;103(5):719–722. doi: 10.7326/0003-4819-103-5-719. [DOI] [PubMed] [Google Scholar]
  8. Frasca D., Adorini L., Landolfo S., Doria G. Enhancing effect of IFN-gamma on helper T cell activity and IL 2 production. J Immunol. 1985 Jun;134(6):3907–3911. [PubMed] [Google Scholar]
  9. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  10. Goldstein G., Scheid M. P., Boyse E. A., Schlesinger D. H., Van Wauwe J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. 1979 Jun 22;204(4399):1309–1310. doi: 10.1126/science.451537. [DOI] [PubMed] [Google Scholar]
  11. Hirsch M. S., Kaplan J. C. Prospects of therapy for infections with human T-lymphotropic virus type III. Ann Intern Med. 1985 Nov;103(5):750–755. doi: 10.7326/0003-4819-103-5-750. [DOI] [PubMed] [Google Scholar]
  12. Lane H. C., Fauci A. S. Immunologic reconstitution in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Nov;103(5):714–718. doi: 10.7326/0003-4819-103-5-714. [DOI] [PubMed] [Google Scholar]
  13. Lane H. C., Masur H., Edgar L. C., Whalen G., Rook A. H., Fauci A. S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983 Aug 25;309(8):453–458. doi: 10.1056/NEJM198308253090803. [DOI] [PubMed] [Google Scholar]
  14. Lazzarin A., Galli M., Moroni M., Cultraro D., Negri C., Parravicini C., Ragni M. C., Fiorenza A. M., Nervetti G., Zanussi C. Linfoadenopatia generalizzata e persistente in tossicodipendenti: aspetti clinici ed epidemiologici. Boll Ist Sieroter Milan. 1984 Sep;63(4):357–365. [PubMed] [Google Scholar]
  15. Meroni P. L., Barcellini W., DeBartolo G., Invernizzi F., Zanussi C. Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from patients with essential mixed cryoglobulinemia. Clin Immunol Immunopathol. 1984 Nov;33(2):245–257. doi: 10.1016/0090-1229(84)90079-5. [DOI] [PubMed] [Google Scholar]
  16. Meroni P. L., Barcellini W., Messina C., De Bartolo G., Capsoni F., Invernizzi F. Defective suppressor cell activity in essential mixed cryoglobulinemia. J Clin Lab Immunol. 1982 Sep;8(3):177–182. [PubMed] [Google Scholar]
  17. Nicholson J. K., McDougal J. S., Spira T. J., Cross G. D., Jones B. M., Reinherz E. L. Immunoregulatory subsets of the T helper and T suppressor cell populations in homosexual men with chronic unexplained lymphadenopathy. J Clin Invest. 1984 Jan;73(1):191–201. doi: 10.1172/JCI111190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pinching A. J. The acquired immune deficiency syndrome. Clin Exp Immunol. 1984 Apr;56(1):1–13. [PMC free article] [PubMed] [Google Scholar]
  19. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984 May 4;224(4648):497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  20. Siegel J. P., Djeu J. Y., Stocks N. I., Masur H., Gelmann E. P., Quinnan G. V., Jr Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes. J Clin Invest. 1985 Jun;75(6):1957–1964. doi: 10.1172/JCI111912. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES